Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the expression of the BCR–ABL1 fusion gene with different chimeric transcripts. Despite the crucial impact of constitutively active tyrosine kinase in CML pathogenesis, aberrant DNA methylation of certain genes p...
Gespeichert in:
| Veröffentlicht in: | Biochemical genetics 2018-06, Vol.56 (3), p.149-175 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 175 |
|---|---|
| container_issue | 3 |
| container_start_page | 149 |
| container_title | Biochemical genetics |
| container_volume | 56 |
| creator | Behzad, Masumeh Maleki Shahrabi, Saeid Jaseb, Kaveh Bertacchini, Jessika Ketabchi, Neda Saki, Najmaldin |
| description | Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the expression of the BCR–ABL1 fusion gene with different chimeric transcripts. Despite the crucial impact of constitutively active tyrosine kinase in CML pathogenesis, aberrant DNA methylation of certain genes plays an important role in disease progression and the development of drug resistance. This article reviews recent findings relevant to the effect of DNA methylation pattern of regulatory genes on various cellular activities such as cell proliferation and survival, as well as cell-signaling molecules in CML. These data might contribute to defining the role of aberrant DNA methylation in disease initiation and progression. However, further studies are needed on the validation of specific aberrant methylation markers regarding the prognosis and prediction of response among the CML patients. |
| doi_str_mv | 10.1007/s10528-018-9841-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1993386103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993603521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-6c62b37b52755c6835e4ad9733c0a78613d4991ea6ff16bbc84e21ecc9203ea83</originalsourceid><addsrcrecordid>eNp1kctu2zAQRYmgRey4-YBsCgLddBE1fEgi2Z2hNg_ATorCXRMUNbaVyqRDSgv_fenYCYICWQ0Gc-6dwVyELij5RgkRV5GSgsmMUJkpmdOMnqAxLQTPcsXEBzQmhJQZU0yO0FmMj6lVJM9P0YgpLiURZIy6aQ0hGNfjH_dTPId-vetM33qHW4erdfCutXi-g863DZ7B8Bc2rfmOK-g6fG16wJV3ffDdJf4V_Mr52MZLbFyDF2sIZgtDn_S_IW69i_AJfVyaLsL5sU7Qn-ufi-o2mz3c3FXTWWa5YH1W2pLVXNQFE0VhS8kLyE2jBOeWGCFLyptcKQqmXC5pWddW5sAoWKsY4WAkn6CvB99t8E8DxF5v2mjTycaBH6KmSnGefAhP6Jf_0Ec_BJeue6ZKwgtGE0UPlA0-xgBLvQ3txoSdpkTvo9CHKHSKQu-j0HvN56PzUG-geVW8_D4B7ADENHIrCG9Wv-v6D_ukkqE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993603521</pqid></control><display><type>article</type><title>Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Behzad, Masumeh Maleki ; Shahrabi, Saeid ; Jaseb, Kaveh ; Bertacchini, Jessika ; Ketabchi, Neda ; Saki, Najmaldin</creator><creatorcontrib>Behzad, Masumeh Maleki ; Shahrabi, Saeid ; Jaseb, Kaveh ; Bertacchini, Jessika ; Ketabchi, Neda ; Saki, Najmaldin</creatorcontrib><description>Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the expression of the BCR–ABL1 fusion gene with different chimeric transcripts. Despite the crucial impact of constitutively active tyrosine kinase in CML pathogenesis, aberrant DNA methylation of certain genes plays an important role in disease progression and the development of drug resistance. This article reviews recent findings relevant to the effect of DNA methylation pattern of regulatory genes on various cellular activities such as cell proliferation and survival, as well as cell-signaling molecules in CML. These data might contribute to defining the role of aberrant DNA methylation in disease initiation and progression. However, further studies are needed on the validation of specific aberrant methylation markers regarding the prognosis and prediction of response among the CML patients.</description><identifier>ISSN: 0006-2928</identifier><identifier>EISSN: 1573-4927</identifier><identifier>DOI: 10.1007/s10528-018-9841-1</identifier><identifier>PMID: 29388070</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aberration ; Apoptosis ; Biochemistry ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Cell fate ; Cell Proliferation ; Cell survival ; Chronic myeloid leukemia ; Deoxyribonucleic acid ; Disease-Free Survival ; DNA ; DNA Methylation ; DNA, Neoplasm - genetics ; DNA, Neoplasm - metabolism ; Drug resistance ; Fusion protein ; Gene expression ; Genes ; Hematopoietic stem cells ; Human Genetics ; Humans ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Malignancy ; Medical Microbiology ; Medical prognosis ; Myeloid leukemia ; Pathogenesis ; Prognosis ; Protein-tyrosine kinase ; Review ; Signaling ; Stem cells ; Survival Rate ; Tyrosine ; Zoology</subject><ispartof>Biochemical genetics, 2018-06, Vol.56 (3), p.149-175</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>Biochemical Genetics is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-6c62b37b52755c6835e4ad9733c0a78613d4991ea6ff16bbc84e21ecc9203ea83</citedby><cites>FETCH-LOGICAL-c372t-6c62b37b52755c6835e4ad9733c0a78613d4991ea6ff16bbc84e21ecc9203ea83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10528-018-9841-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10528-018-9841-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27911,27912,41475,42544,51306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29388070$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Behzad, Masumeh Maleki</creatorcontrib><creatorcontrib>Shahrabi, Saeid</creatorcontrib><creatorcontrib>Jaseb, Kaveh</creatorcontrib><creatorcontrib>Bertacchini, Jessika</creatorcontrib><creatorcontrib>Ketabchi, Neda</creatorcontrib><creatorcontrib>Saki, Najmaldin</creatorcontrib><title>Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response</title><title>Biochemical genetics</title><addtitle>Biochem Genet</addtitle><addtitle>Biochem Genet</addtitle><description>Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the expression of the BCR–ABL1 fusion gene with different chimeric transcripts. Despite the crucial impact of constitutively active tyrosine kinase in CML pathogenesis, aberrant DNA methylation of certain genes plays an important role in disease progression and the development of drug resistance. This article reviews recent findings relevant to the effect of DNA methylation pattern of regulatory genes on various cellular activities such as cell proliferation and survival, as well as cell-signaling molecules in CML. These data might contribute to defining the role of aberrant DNA methylation in disease initiation and progression. However, further studies are needed on the validation of specific aberrant methylation markers regarding the prognosis and prediction of response among the CML patients.</description><subject>Aberration</subject><subject>Apoptosis</subject><subject>Biochemistry</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell fate</subject><subject>Cell Proliferation</subject><subject>Cell survival</subject><subject>Chronic myeloid leukemia</subject><subject>Deoxyribonucleic acid</subject><subject>Disease-Free Survival</subject><subject>DNA</subject><subject>DNA Methylation</subject><subject>DNA, Neoplasm - genetics</subject><subject>DNA, Neoplasm - metabolism</subject><subject>Drug resistance</subject><subject>Fusion protein</subject><subject>Gene expression</subject><subject>Genes</subject><subject>Hematopoietic stem cells</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Malignancy</subject><subject>Medical Microbiology</subject><subject>Medical prognosis</subject><subject>Myeloid leukemia</subject><subject>Pathogenesis</subject><subject>Prognosis</subject><subject>Protein-tyrosine kinase</subject><subject>Review</subject><subject>Signaling</subject><subject>Stem cells</subject><subject>Survival Rate</subject><subject>Tyrosine</subject><subject>Zoology</subject><issn>0006-2928</issn><issn>1573-4927</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kctu2zAQRYmgRey4-YBsCgLddBE1fEgi2Z2hNg_ATorCXRMUNbaVyqRDSgv_fenYCYICWQ0Gc-6dwVyELij5RgkRV5GSgsmMUJkpmdOMnqAxLQTPcsXEBzQmhJQZU0yO0FmMj6lVJM9P0YgpLiURZIy6aQ0hGNfjH_dTPId-vetM33qHW4erdfCutXi-g863DZ7B8Bc2rfmOK-g6fG16wJV3ffDdJf4V_Mr52MZLbFyDF2sIZgtDn_S_IW69i_AJfVyaLsL5sU7Qn-ufi-o2mz3c3FXTWWa5YH1W2pLVXNQFE0VhS8kLyE2jBOeWGCFLyptcKQqmXC5pWddW5sAoWKsY4WAkn6CvB99t8E8DxF5v2mjTycaBH6KmSnGefAhP6Jf_0Ec_BJeue6ZKwgtGE0UPlA0-xgBLvQ3txoSdpkTvo9CHKHSKQu-j0HvN56PzUG-geVW8_D4B7ADENHIrCG9Wv-v6D_ukkqE</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Behzad, Masumeh Maleki</creator><creator>Shahrabi, Saeid</creator><creator>Jaseb, Kaveh</creator><creator>Bertacchini, Jessika</creator><creator>Ketabchi, Neda</creator><creator>Saki, Najmaldin</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7SS</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180601</creationdate><title>Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response</title><author>Behzad, Masumeh Maleki ; Shahrabi, Saeid ; Jaseb, Kaveh ; Bertacchini, Jessika ; Ketabchi, Neda ; Saki, Najmaldin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-6c62b37b52755c6835e4ad9733c0a78613d4991ea6ff16bbc84e21ecc9203ea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aberration</topic><topic>Apoptosis</topic><topic>Biochemistry</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell fate</topic><topic>Cell Proliferation</topic><topic>Cell survival</topic><topic>Chronic myeloid leukemia</topic><topic>Deoxyribonucleic acid</topic><topic>Disease-Free Survival</topic><topic>DNA</topic><topic>DNA Methylation</topic><topic>DNA, Neoplasm - genetics</topic><topic>DNA, Neoplasm - metabolism</topic><topic>Drug resistance</topic><topic>Fusion protein</topic><topic>Gene expression</topic><topic>Genes</topic><topic>Hematopoietic stem cells</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Malignancy</topic><topic>Medical Microbiology</topic><topic>Medical prognosis</topic><topic>Myeloid leukemia</topic><topic>Pathogenesis</topic><topic>Prognosis</topic><topic>Protein-tyrosine kinase</topic><topic>Review</topic><topic>Signaling</topic><topic>Stem cells</topic><topic>Survival Rate</topic><topic>Tyrosine</topic><topic>Zoology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Behzad, Masumeh Maleki</creatorcontrib><creatorcontrib>Shahrabi, Saeid</creatorcontrib><creatorcontrib>Jaseb, Kaveh</creatorcontrib><creatorcontrib>Bertacchini, Jessika</creatorcontrib><creatorcontrib>Ketabchi, Neda</creatorcontrib><creatorcontrib>Saki, Najmaldin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Behzad, Masumeh Maleki</au><au>Shahrabi, Saeid</au><au>Jaseb, Kaveh</au><au>Bertacchini, Jessika</au><au>Ketabchi, Neda</au><au>Saki, Najmaldin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response</atitle><jtitle>Biochemical genetics</jtitle><stitle>Biochem Genet</stitle><addtitle>Biochem Genet</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>56</volume><issue>3</issue><spage>149</spage><epage>175</epage><pages>149-175</pages><issn>0006-2928</issn><eissn>1573-4927</eissn><abstract>Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the expression of the BCR–ABL1 fusion gene with different chimeric transcripts. Despite the crucial impact of constitutively active tyrosine kinase in CML pathogenesis, aberrant DNA methylation of certain genes plays an important role in disease progression and the development of drug resistance. This article reviews recent findings relevant to the effect of DNA methylation pattern of regulatory genes on various cellular activities such as cell proliferation and survival, as well as cell-signaling molecules in CML. These data might contribute to defining the role of aberrant DNA methylation in disease initiation and progression. However, further studies are needed on the validation of specific aberrant methylation markers regarding the prognosis and prediction of response among the CML patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29388070</pmid><doi>10.1007/s10528-018-9841-1</doi><tpages>27</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-2928 |
| ispartof | Biochemical genetics, 2018-06, Vol.56 (3), p.149-175 |
| issn | 0006-2928 1573-4927 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1993386103 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aberration Apoptosis Biochemistry Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Cell fate Cell Proliferation Cell survival Chronic myeloid leukemia Deoxyribonucleic acid Disease-Free Survival DNA DNA Methylation DNA, Neoplasm - genetics DNA, Neoplasm - metabolism Drug resistance Fusion protein Gene expression Genes Hematopoietic stem cells Human Genetics Humans Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Malignancy Medical Microbiology Medical prognosis Myeloid leukemia Pathogenesis Prognosis Protein-tyrosine kinase Review Signaling Stem cells Survival Rate Tyrosine Zoology |
| title | Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T03%3A19%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aberrant%20DNA%20Methylation%20in%20Chronic%20Myeloid%20Leukemia:%20Cell%20Fate%20Control,%20Prognosis,%20and%20Therapeutic%20Response&rft.jtitle=Biochemical%20genetics&rft.au=Behzad,%20Masumeh%20Maleki&rft.date=2018-06-01&rft.volume=56&rft.issue=3&rft.spage=149&rft.epage=175&rft.pages=149-175&rft.issn=0006-2928&rft.eissn=1573-4927&rft_id=info:doi/10.1007/s10528-018-9841-1&rft_dat=%3Cproquest_cross%3E1993603521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993603521&rft_id=info:pmid/29388070&rfr_iscdi=true |